COMMUNIQUÉS West-GlobeNewswire

PatchMD Named the World’s #1 Vitamin Patch Brand in 2026 — And It’s Not Even Close
17/03/2026
Independent research confirms PatchMD holds 18% global market share in a booming $800M+ category projected to hit $1.78 billion by 2032. LAS VEGAS, NV, March 17, 2026 (GLOBE NEWSWIRE) -- The vitamin patch industry just [...]
Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19
17/03/2026
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive [...]
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1. [...]
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
17/03/2026
Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a [...]
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
17/03/2026
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
17/03/2026
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study [...]
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
17/03/2026
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro [...]
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
17/03/2026
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: [...]
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
17/03/2026
Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies MALVERN, Pa., March 17 [...]
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
17/03/2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- The Organoid COMMONS (Consortium for Organoid Manufacturing, Measurement, Optimization, and Network for Standards) is pleased to announce formal establishment of its first [...]
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
17/03/2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented [...]
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
17/03/2026
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of [...]
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 [...]
Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™
17/03/2026
New digital card platform offers a unified alternative to fragmented manufacturer programs, giving employers enhanced control over the Budget, Behavior, and Biology of obesity care MOUNTAIN VIEW, Calif., March 17, 2026 [...]
Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Address Evolving NHS Cyber Security and Compliance Challenges
17/03/2026
Imprivata Enterprise Access Management now offers facial recognition, AI-powered behavioral analytics, and high-assurance identity verification to further streamline access to personal and shared-use devices, increase [...]
Transactions in connection with share buy-back program
17/03/2026
Company announcement no. 5 - 26 17 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic
17/03/2026
-- Financing brings total funds committed to date to >$95 million -- Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline [...]
CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA
17/03/2026
Cambridge-based surgical robotics company contributes majority of surgical data to world’s largest open healthcare robotics dataset Cambridge, UK and San Jose, California – 16 March 2026, CMR Surgical (“CMR”), the [...]
Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference
17/03/2026
LONDON and PHILADELPHIA, March 17, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology [...]

Pages